Top

Published in:

01-04-2018 | Original Article

An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression

Authors: Rika Fujii, Caroline Jochems, Sarah R. Tritsch, Hing C. Wong, Jeffrey Schlom, James W. Hodge

Published in: Cancer Immunology, Immunotherapy | Issue 4/2018

Abstract

Natural killer (NK) cells are innate cytotoxic lymphocytes that play a fundamental role in the immunosurveillance of cancers. NK cells of cancer patients exhibit impaired function mediated by immunosuppressive factors released from the tumor microenvironment (TME), such as transforming growth factor (TGF)-β1. An interleukin (IL)-15 superagonist/IL-15 receptor α fusion complex (IL-15SA/IL-15RA; ALT-803) activates the IL-15 receptor on CD8 T cells and NK cells, and has shown significant anti-tumor activity in several in vivo studies. This in vitro study investigated the efficacy of IL-15SA/IL-15RA on TGF-β1-induced suppression of NK cell-cytotoxic function. IL-15SA/IL-15RA inhibited TGF-β1 from decreasing NK cell lysis of four of four tumor cell lines (H460, LNCap, MCF7, MDA-MB-231). IL-15SA/IL-15RA rescued healthy donor and cancer patient NK cell-cytotoxicity, which had previously been suppressed by culture with TGF-β1. TGF-β1 downregulated expression of NK cell-activating markers and cytotoxic granules, such as CD226, NKG2D, NKp30, granzyme B, and perforin. Smad2/3 signaling was responsible for this TGF-β1-induced downregulation of NK cell-activating markers and cytotoxic granules. IL-15SA/IL-15RA blocked Smad2/3-induced transcription, resulting in the rescue of NK cell-cytotoxic function from TGF-β1-induced suppression. These findings suggest that in addition to increasing NK cell function via promoting the IL-15 signaling pathway, IL-15SA/IL-15RA can function as an inhibitor of TGF-β1 signaling, providing a potential remedy for NK cell dysfunction in the immunosuppressive tumor microenvironment.

Available only for authorised users

Carotta S (2016) Targeting NK cells for anticancer immunotherapy: clinical and preclinical approaches. Front Immunol 7:152. https://doi.org/10.3389/fimmu.2016.00152 CrossRefPubMedPubMedCentral

Guillerey C, Huntington ND, Smyth MJ (2016) Targeting natural killer cells in cancer immunotherapy. Nat Immunol 17:1025–1036. https://doi.org/10.1038/ni.3518 CrossRefPubMed

Baginska J, Viry E, Paggetti J, Medves S, Berchem G, Moussay E, Janji B (2013) The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Front Immunol 4:490. https://doi.org/10.3389/fimmu.2013.00490 CrossRefPubMedPubMedCentral

Tsushima H, Kawata S, Tamura S et al. (1996) High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression. Gastroenterology. 110: 375–382CrossRef

Ikushima H, Miyazono K (2010) TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 10: 415–424. https://doi.org/10.1038/nrc2853 CrossRef

Lippitz BE (2013) Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 14:e218–228. https://doi.org/10.1016/S1470-2045(12)70582-X CrossRef

Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P (2010) The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol. 10: 554–567. https://doi.org/10.1038/nri2808 CrossRef

Yu J, Wei M, Becknell B et al. (2006) Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity. 24: 575–590. https://doi.org/10.1016/j.immuni.2006.03.016 CrossRef

Trotta R, Dal Col J, Yu J et al (2008) TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol 181:3784–3792CrossRefPubMedPubMedCentral

10.

Rosenberg SA (2014) IL-2: the first effective immunotherapy for human cancer. J Immunol 192:5451–5458. https://doi.org/10.4049/jimmunol.1490019 CrossRefPubMed

11.

Mier JW, Brandon EP, Libby P, Janicka MW, Aronson FR (1989) Activated endothelial cells resist lymphokine-activated killer cell-mediated injury. Possible role of induced cytokines in limiting capillary leak during IL-2 therapy. J Immunol 143:2407–2414PubMed

12.

Sim GC, Radvanyi L (2014) The IL-2 cytokine family in cancer immunotherapy. Cytokine Growth Factor Rev. 25: 377–390. https://doi.org/10.1016/j.cytogfr.2014.07.018 CrossRef

13.

Conlon KC, Lugli E, Welles HC et al (2015) Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol 33:74–82. https://doi.org/10.1200/JCO.2014.57.3329 CrossRefPubMed

14.

Zamai L, Ponti C, Mirandola P, Gobbi G, Papa S, Galeotti L, Cocco L, Vitale M (2007) NK cells and cancer. J Immunol 178:4011–4016CrossRefPubMed

15.

Kobayashi H, Carrasquillo JA, Paik CH, Waldmann TA, Tagaya Y (2000) Differences of biodistribution, pharmacokinetics, and tumor targeting between interleukins 2 and 15. Cancer Res 60:3577–3583PubMed

16.

Zhu X, Marcus WD, Xu W, Lee HI, Han K, Egan JO, Yovandich JL, Rhode PR, Wong HC (2009) Novel human interleukin-15 agonists. J Immunol. 183: 3598–3607. https://doi.org/10.4049/jimmunol.0901244 CrossRef

17.

Han KP, Zhu X, Liu B et al. (2011) IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization. Cytokine. 56: 804–810. https://doi.org/10.1016/j.cyto.2011.09.028 CrossRef

18.

Rubinstein MP, Kovar M, Purton JF, Cho JH, Boyman O, Surh CD, Sprent J (2006) Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci USA 103:9166–9171. https://doi.org/10.1073/pnas.0600240103 CrossRefPubMedPubMedCentral

19.

Stoklasek TA, Schluns KS, Lefrancois L (2006) Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol 177:6072–6080CrossRefPubMedPubMedCentral

20.

Xu W, Jones M, Liu B et al (2013) Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor alphaSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res 73:3075–3086. https://doi.org/10.1158/0008-5472.CAN-12-2357 CrossRefPubMedPubMedCentral

21.

Gomes-Giacoia E, Miyake M, Goodison S et al (2014) Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion. PLoS One 9:e96705. https://doi.org/10.1371/journal.pone.0096705 CrossRefPubMedPubMedCentral

22.

Mathios D, Park CK, Marcus WD, Alter S, Rhode PR, Jeng EK, Wong HC, Pardoll DM, Lim M (2016) Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model. Int J Cancer. 138: 187–194. https://doi.org/10.1002/ijc.29686 CrossRef

23.

Kim PS, Kwilas AR, Xu W, Alter S, Jeng EK, Wong HC, Schlom J, Hodge JW (2016) IL-15 superagonist/IL-15RalphaSushi-Fc fusion complex (IL-15SA/IL-15RalphaSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8 + T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas. Oncotarget 7:16130–16145. https://doi.org/10.18632/oncotarget.7470 PubMedPubMedCentral

24.

Felices M, Chu S, Kodal B et al. (2017) IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer. Gynecol Oncol. 145: 453–461. https://doi.org/10.1016/j.ygyno.2017.02.028 CrossRef

25.

Rhode PR, Egan JO, Xu W et al (2016) Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models. Cancer Immunol Res 4:49–60. https://doi.org/10.1158/2326-6066.CIR-15-0093-T CrossRefPubMed

26.

Jochems C, Tucker JA, Tsang KY, Madan RA, Dahut WL, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J (2014) A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol Immunother. 63: 407–418. https://doi.org/10.1007/s00262-014-1524-0

27.

Donahue RN, Lepone LM, Grenga I, Jochems C, Fantini M, Madan RA, Heery CR, Gulley JL, Schlom J (2017) Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody. J Immunother Cancer 5:20. https://doi.org/10.1186/s40425-017-0220-y CrossRefPubMedPubMedCentral

28.

Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, Schlom J (2015) Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res 3:1148–1157. https://doi.org/10.1158/2326-6066.CIR-15-0059 CrossRefPubMedPubMedCentral

29.

Chen JQ, Lee JH, Herrmann MA, Park KS, Heldman MR, Goldsmith PK, Wang Y, Giaccone G (2013) Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer. Mol Cancer Ther 12:2601–2613. https://doi.org/10.1158/1535-7163.MCT-13-0074 CrossRefPubMed

30.

Roberti MP, Rocca YS, Amat M et al. (2012) IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients. Breast Cancer Res Treat. 136: 659–671. https://doi.org/10.1007/s10549-012-2287-y CrossRef

31.

Lee HM, Kim KS, Kim J (2014) A comparative study of the effects of inhibitory cytokines on human natural killer cells and the mechanistic features of transforming growth factor-beta. Cell Immunol 290:52–61. https://doi.org/10.1016/j.cellimm.2014.05.001 CrossRefPubMed

32.

Wilson EB, El-Jawhari JJ, Neilson AL, Hall GD, Melcher AA, Meade JL, Cook GP (2011) Human tumour immune evasion via TGF-beta blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. PLoS One 6:e22842. https://doi.org/10.1371/journal.pone.0022842 CrossRefPubMedPubMedCentral

33.

Castriconi R, Cantoni C, Della Chiesa M et al (2003) Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 100:4120–4125. https://doi.org/10.1073/pnas.0730640100 CrossRefPubMedPubMedCentral

34.

Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 425: 577–584. https://doi.org/10.1038/nature02006 CrossRef

35.

Gaarenstroom T, Hill CS (2014) TGF-beta signaling to chromatin: how Smads regulate transcription during self-renewal and differentiation. Semin Cell Dev Biol. 32: 107–118. https://doi.org/10.1016/j.semcdb.2014.01.009 CrossRef

36.

Wong C, Rougier-Chapman EM, Frederick JP, Datto MB, Liberati NT, Li JM, Wang XF (1999) Smad3-Smad4 and AP-1 complexes synergize in transcriptional activation of the c-Jun promoter by transforming growth factor beta. Mol Cell Biol 19:1821–1830CrossRefPubMedPubMedCentral

37.

Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM (1998) Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 17: 3091–3100. https://doi.org/10.1093/emboj/17.11.3091 CrossRef

38.

Nagarajan RP, Zhang J, Li W, Chen Y (1999) Regulation of Smad7 promoter by direct association with Smad3 and Smad4. J Biol Chem 274:33412–33418CrossRefPubMed

39.

Yokobori T, Nishiyama M (2017) TGF-beta signaling in gastrointestinal cancers: progress in basic and clinical research. J Clin Med. 6. https://doi.org/10.3390/jcm6010011

40.

Berchem G, Noman MZ, Bosseler M et al (2016) Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-beta and miR23a transfer. Oncoimmunology 5:e1062968. https://doi.org/10.1080/2162402X.2015.1062968 CrossRefPubMed

41.

Chandran PA, Keller A, Weinmann L et al (2014) The TGF-beta-inducible miR-23a cluster attenuates IFN-gamma levels and antigen-specific cytotoxicity in human CD8(+) T cells. J Leukoc Biol 96: 633–645. https://doi.org/10.1189/jlb.3A0114-025R CrossRef

42.

Rocca YS, Roberti MP, Julia EP et al (2016) Phenotypic and functional dysregulated blood NK cells in colorectal cancer patients can be activated by cetuximab plus IL-2 or IL-15. Front Immunol 7:413. https://doi.org/10.3389/fimmu.2016.00413 CrossRefPubMedPubMedCentral

43.

Rosario M, Liu B, Kong L et al (2016) The IL-15-based ALT-803 complex enhances fcgammariiia-triggered NK Cell responses and in vivo clearance of B cell lymphomas. Clin Cancer Res 22:596–608. https://doi.org/10.1158/1078-0432.CCR-15-1419 CrossRefPubMed

44.

Lee JC, Lee KM, Kim DW, Heo DS (2004) Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 172:7335–7340CrossRefPubMed

45.

Viel S, Marcais A, Guimaraes FS et al (2016) TGF-beta inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci Signal 9:ra19. https://doi.org/10.1126/scisignal.aad1884 CrossRefPubMed

46.

Mao Y, van Hoef V, Zhang X et al (2016) IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells. Blood 128:1475–1489. https://doi.org/10.1182/blood-2016-02-698027 CrossRefPubMedPubMedCentral

47.

Fujii R, Schlom J, Hodge JW (2017) A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab. J Neurosurg. 1–9. https://doi.org/10.3171/2017.1.JNS162610

48.

Hodge G, Hodge S, Yeo A, Nguyen P, Hopkins E, Holmes-Liew CL, Reynolds PN, Holmes M (2017) BOS Is associated with increased cytotoxic proinflammatory CD8 T, NKT-like, and NK Cells in the small airways. Transplantation 101:2469–2476. https://doi.org/10.1097/TP.0000000000001592 CrossRefPubMed

49.

Jochems C, Hodge JW, Fantini M, Tsang KY, Vandeveer AJ, Gulley JL, Schlom J (2017) ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody. Int J Cancer. 141: 583–593. https://doi.org/10.1002/ijc.30767 CrossRef

Title: An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression
Authors: Rika Fujii
Caroline Jochems
Sarah R. Tritsch
Hing C. Wong
Jeffrey Schlom
James W. Hodge
Publication date: 01-04-2018
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 4/2018
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-018-2121-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2018

Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells

Reduction of myeloid-derived suppressor cells reinforces the anti-solid tumor effect of recipient leukocyte infusion in murine neuroblastoma-bearing allogeneic bone marrow chimeras

The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma

Linear doggybone DNA vaccine induces similar immunological responses to conventional plasmid DNA independently of immune recognition by TLR9 in a pre-clinical model

IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients

Human c-SRC kinase (CSK) overexpression makes T cells dummy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer